Delcath Systems (DCTH) announced that its proprietary CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion has been included as a recommended liver-directed regional therapy option in the newly published Uveal Melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. M-PHP is also recognized in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Metastatic Uveal Melanoma. HEPZATO KIT is included as a Category 2A recommended treatment option for appropriate patients with hepatic-dominant metastatic uveal melanoma. M-PHP has been listed as a liver-directed therapy option in NCCN guidelines for several years, predating the 2023 FDA approval of HEPZATO KIT.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems management to meet with Craig Hallum
- Delcath Systems Charts Profitable Path Amid Heavy Investment
- Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma
- Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology
- Delcath Systems: Procedure-Driven Growth, Pricing Power, and CHOPIN Trial Catalysts Support Buy Rating